Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death

BEIJING - Still expanding globally after engineering the pharmaceutical world's most massive merger of the year, the titan-like Pfizer is partnering with the comparatively tiny contract research organization Crown Bioscience to develop new medicines aimed at fighting cancers that are prevalent in Asia, according to a leading Pfizer Asia executive

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip